antiparkinson/camellia

BACKGROUND The anti-Parkinson monoamine oxidase B inhibitor rasagiline appears to be the first neuroprotective disease-modifying therapy in early-stage Parkinson's disease (PD). OBJECTIVE Using a polypharmacy paradigm, we tested whether the distinct neuroprotective pharmacological profile of

Neurological disorders and their sequelae, as of the widespread and critical humans complications, affect the body's nervous systems, organ functions, and behaviors. According to WHO, neurological disorders are currently predicted to affect more than one billion people globally. It is